KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Operating Leases (2019 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Operating Leases for 7 consecutive years, with $30.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases rose 10.89% to $30.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $30.4 million, a 10.89% increase, with the full-year FY2025 number at $30.4 million, up 10.89% from a year prior.
  • Operating Leases was $30.4 million for Q4 2025 at Supernus Pharmaceuticals, down from $31.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $47.8 million in Q4 2021 to a low of $27.4 million in Q4 2024.
  • A 5-year average of $37.0 million and a median of $36.5 million in 2023 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: grew 15.36% in 2023, then crashed 34.06% in 2024.
  • Supernus Pharmaceuticals' Operating Leases stood at $47.8 million in 2021, then dropped by 24.65% to $36.0 million in 2022, then increased by 15.36% to $41.5 million in 2023, then plummeted by 34.06% to $27.4 million in 2024, then grew by 10.89% to $30.4 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Operating Leases are $30.4 million (Q4 2025), $31.4 million (Q3 2025), and $32.3 million (Q1 2025).